Celularity CELU
NASDAQ CELU
$0.99 -0.06 (-5.30%)
As of: Oct 23, 2026 · 2:43 PM EDT

Celularity (CELU) Asset Writedowns and Impairment (2020 - 2025)

Updated

Celularity (CELU) posted Asset Writedowns and Impairment of $2.89 million for FY2025, compared with $186,000 in FY2024.

Analysis

Celularity (CELU) Asset Writedowns and Impairment (2020 - 2025) Analysis & Trends

Since FY2020, Celularity has reported Asset Writedowns and Impairment for 5 years.

  • Annual Asset Writedowns and Impairment shows a five-year compound annual growth rate of -53.2% (FY2020 to FY2025).
  • Annual Asset Writedowns and Impairment has run from a low of $186,000 in FY2024 to a high of $112.35 million in FY2023 over five years.
  • Business Quant data shows CELU's Asset Writedowns and Impairment at $186,000 in FY2024 (-99.8%), $112.35 million in FY2023 and $3.61 million in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,127.89 Bn 1,096.47 Bn 19.71 Bn
2 Johnson & Johnson 635.11 Bn 554.97 Bn 17.30 Bn
3 AbbVie 504.69 Bn 477.80 Bn 12.70 Bn
4 Merck 358.24 Bn 312.62 Bn 12.21 Bn
5 Novartis Ag 290.13 Bn 254.12 Bn 11.24 Bn
6 Astrazeneca 265.05 Bn 238.74 Bn 12.86 Bn
7 Amgen 237.87 Bn 193.27 Bn 7.24 Bn
8 Gilead Sciences 194.91 Bn 169.11 Bn 6.22 Bn
9 Pfizer 171.28 Bn 117.93 Bn 10.94 Bn
10 Celularity 29.04 Mn 21.79 Mn 3.09 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 86,000.00
Mar 31, 2025 -123,000.00
Dec 31, 2024 186,000.00
Sep 30, 2023 82.71 Mn
Mar 31, 2023 29.63 Mn
Dec 31, 2022 3.61 Mn
Sep 30, 2020 129.40 Mn
API Access

Celularity Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=CELU&period=max&api_key=YOUR_API_KEY